Aspirin resistance. Salicylates
Conditions
Interventions
Intervention 1: Testing group1: aspirin (80 mg) , 1 pill per day. Intervention 2: Testing group 2: aspirin (81mg), 1 pill per day. Intervention 3: Testing group3: aspirin (100 mg), 1 pill per
Diagnosis
Testing group1: aspirin (80 mg) , 1 pill per day
Testing group 2: aspirin (81mg), 1 pill per day
Testing group3: aspirin (100 mg), 1 pill per day
Testing group4: aspirin (325 mg), 1 pill per day
Control group : placebo, 1 pill per day
Sponsors
Lorestan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 149 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All participants 35 years old and older , who are living in Borujerd city.Participants should have used ASA at least for 5 days. Exclusion criteria: History of acquired or congenital coagulation disorders ,chronic kidney diseases and blood discrasia were excluded from the study. Consumption of some medications such as other platelet inhibitors and anticoagulants such as warfarin ; and volunteers with platelet count less than 150000.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding time and urinary thromboxane B2. Timepoint: Once , after intervention. Method of measurement: IVY method.;Thromboxane B2. Timepoint: Once after intervention. Method of measurement: Urinary sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ali Maleki
Lorestan University of Medical Sciences
Outcome results
None listed